Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 1;11(1):120.
doi: 10.1186/s13550-021-00862-y.

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma

Na Sun #  1 , Marija Trajkovic-Arsic #  2   3 , Fengxia Li #  1 , Yin Wu  1 , Corinna Münch  2   3 , Thomas Kunzke  1 , Annette Feuchtinger  1 , Katja Steiger  4   5 , Anna Melissa Schlitter  4   5 , Wilko Weichert  4   5   6 , Irene Esposito  7 , Jens T Siveke  8   9 , Axel Walch  10
Affiliations

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma

Na Sun et al. EJNMMI Res. .

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies to date. The impressively developed stroma that surrounds and modulates the behavior of cancer cells is one of the main factors regulating the PDAC growth, metastasis and therapy resistance. Here, we postulate that stromal and cancer cell compartments differentiate in protein/lipid glycosylation patterns and analyze differences in glycan fragments in those compartments with clinicopathologic correlates.

Results: We analyzed native glycan fragments in 109 human FFPE PDAC samples using high mass resolution matrix-assisted laser desorption/ionization Fourier-transform ion cyclotron resonance mass spectrometric imaging (MALDI-FT-ICR-MSI). Our method allows detection of native glycan fragments without previous digestion with PNGase or any other biochemical reaction. With this method, 8 and 18 native glycans were identified as uniquely expressed in only stromal or only cancer cell compartment, respectively. Kaplan-Meier survival model identified glycan fragments that are expressed in cancer cell or stromal compartment and significantly associated with patient outcome. Among cancer cell region-specific glycans, 10 predicted better and 6 worse patient survival. In the stroma, 1 glycan predicted good and 4 poor patient survival. Using factor analysis as a dimension reduction method, we were able to group the identified glycans in 2 factors. Multivariate analysis revealed that these factors can be used as independent survival prognostic elements with regard to the established Union for International Cancer Control (UICC) classification both in tumor and stroma regions.

Conclusion: Our method allows in situ detection of naturally occurring glycans in FFPE samples of human PDAC tissue and highlights the differences among glycans found in stromal and cancer cell compartment offering a basis for further exploration on the role of specific glycans in cancer-stroma communication.

Keywords: Glycans; MALDI-FT-ICR-MSI; PDAC.

PubMed Disclaimer

Conflict of interest statement

WW has attended Advisory Boards and served as speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Illumina, Siemens, Agilent, ADC, GSK and Molecular Health. WW receives research funding from Roche, MSD, BMS and AstraZeneca, all outside the submitted work; JTS reports the following disclosures: Bristol Myers Squibb, Celgene, Roche (Research Funding); AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Immunocore, Novartis, Roche, Shire (Consulting or advisory role); AstraZeneca, Aurikamed, Baxalta, Bristol Myers Squibb, Celgene, Falk Foundation, iomedico, Immunocore, Novartis, Roche, Shire (honoraria); minor equity in iTheranostics and Pharma15 (< 3%) and member of the Board of Directors for Pharma15, all outside the submitted work. KS is member of the advisory board of TRIMT and received research funding from Roche, all outside the submitted work. KS has a patent filed for a radiopharmaceutical compound. MS served as speaker and scientific advisor for Roche, MSD and BioNTech.

Figures

Fig. 1
Fig. 1
a Ortho-PLSDA of cancer cell and stroma region based on glycan intensities. b Venn diagram indicating common and distinct glycan fragments detected in cancer cell and stroma regions, respectively. c Example of glycan fragments differently expressed in tumor and stroma region, respectively. Co-visualization of HexHexNAcS (red color) and N-Acetylhexosamine sulfate (green color) representing different distributions in the cancer cell and stroma regions
Fig. 2
Fig. 2
a Kaplan–Meier analysis of glycan fragments in cancer region. Blue lines indicate survival in patients with high intensity of the respective mass. Red lines indicate survival in patients with low intensity of the respective mass. Example Kaplan–Meier curves of 4 good prognosis and 4 poor prognosis glycan masses in cancer cell region are shown. In the upper panel, a high abundance of Hex-HexNAcS (m/z 462.0937), Hex-HexNAcS-HexNAc (m/z 665.1725), dHex-HexS (m/z 405.0710) and NeuAc-Hex-HexNAcP (m/z 753.1975) in cancer cell regions was associated with good prognosis. In contrast, in lower panel, high abundance of HexA (m/z 193.0350), chondroitin/hyaluronan (m/z 378.1050), dHex-Hex-HexAMe (m/z 515.1625) and (m/z 599.1955) HexNAc-HexA-HexNAc was associated with poor patient prognosis. b Kaplan–Meier analysis of glycan fragments in the stroma region. Blue lines indicate survival in patients with high intensity of the respective mass. Red lines indicate survival in patients with low intensity of the respective mass. High abundance of HexS (m/z 259.0135) in stroma regions was associated with good prognosis. High abundance of HexNAcS (m/z 282.0290), HexA-HexNAc (m/z 396.1150), HexNAcSS (m/z 401.9785) and HexA-HexNAcS (m/z 476.0725) in stroma regions was associated with poor prognosis
Fig. 3
Fig. 3
a Multivariate factor analysis of significant glycan fragments identifies prognostic glycan factors in cancer cell region. b Multivariate factor analysis of significant glycan fragments identifies prognostic glycan factors in stromal region. The numbers on the arrows pointing from the factors to the individual glycan fragments represent the factor loading of each individual glycan fragment on that factor, which quantifies the extent to which the glycan fragment is related to a given factor. Values close to 1 or − 1 represent strong relation, while values close to 0 indicate weak relation. Blue line indicates high score of the factor. Red line indicates low score of the factor
See this image and copyright information in PMC

References

    1. Chan-Seng-Yue M, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52(2):231–240. doi: 10.1038/s41588-019-0566-9. - DOI - PubMed
    1. Collisson EA, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–503. doi: 10.1038/nm.2344. - DOI - PMC - PubMed
    1. Bailey P, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52. doi: 10.1038/nature16965. - DOI - PubMed
    1. Aung KL, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344–1354. doi: 10.1158/1078-0432.CCR-17-2994. - DOI - PMC - PubMed
    1. Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487–505. doi: 10.1038/s41575-020-0300-1. - DOI - PMC - PubMed

LinkOut - more resources